- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04224922
Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer
A Prospective, Belgian Multi-center, Single-arm, Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Aalst, Belgium, 9300
- Onze Lieve Vrouw Ziekenhuis
-
Arlon, Belgium, 6700
- Cliniques Sud Luxembourg
-
Bonheiden, Belgium, 2820
- Imelda Ziekenhuis
-
Brasschaat, Belgium, 2930
- AZ Klina
-
Brugge, Belgium, 8310
- St Lucas
-
Brussels, Belgium, 1000
- Institut Jules Bordet
-
Edegem, Belgium, 2650
- Universitaire Ziekenhuis Antwerpen
-
Gent, Belgium, 9000
- AZ Maria Middelares
-
Gent, Belgium, 9000
- AZ St Lucas
-
Kortrijk, Belgium, 8500
- Az Groeninge
-
Leuven, Belgium, 3000
- UZ Leuven
-
Liège, Belgium, 4000
- CHU Sart-Tilman
-
Liège, Belgium, 4000
- CHR Citadelle
-
Namur, Belgium, 5000
- CMSE
-
Ottignies, Belgium, 1340
- Clinique St Pierre
-
Tournai, Belgium, 7500
- CHwapi
-
Verviers, Belgium, 4800
- CHR Verviers
-
Yvoir, Belgium, 5530
- CHU Mont-Godinne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Stage II-III operable triple negative (ER and PR < 10%; Her2 IHC 0-1 or FISH <2.0) breast cancer in women age > 18. For patients aged 65 or older the G8 geriatric screening test should be > 14 (on a total of 17).
- Baseline mammography, US. MR of the breast on clinical indication.
- FNA of suspicious axillary lymph node is indicated
- Pre-treatment SN biopsy is indicated in clinical N0
- Measurable loco-regional disease
Adequate bone marrow function, defined as
- Absolute neutrophil count(ANC) >1500*109/L
- Platelet count >100.000*109/L
Adequate liver function defined as
- Serum(total) bilirubin <1.5*upper limit of normal(ULN), unless the patient has documented Gilbert's Syndrome
- AST and/or ALT <2.5*ULN
- Alkaline phosphatase <2.5*ULN
- Normal cardiac function measured by ultrasound with a left ventricular function > 55%
- Creatinine clearance > 40 ml/min according to local laboratory standard (MDRD, CDK-epi, Cockroft-Gault, or other established formula to calculate renal function)
Exclusion Criteria:
- T4d breast tumor
- Bilateral breast cancer
- Other invasive cancer in the past except for a localized squamous cell cancer or basal cell of the skin or an in situ squamous cell cancer of the cervix.
- Pregnant or lactating patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single-arm
weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
-The rate of pCR in the breast and axilla (ypT0/is, ypN0)
Time Frame: 20 weeks
|
20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of tumor infiltrating lymphocytes on the residual tumor
Time Frame: 20 weeks
|
Histopathological analysis of the lymphocyte infiltrate is performed on hematoxylin and eosin- stained sections of the core biopsies and afterwords on the resection specimen after neoadjuvant chemotherapy.
Ancillary techniques and immunohistochemistry have no additional value upon this date, and are not recommanded.
The overall assessment has to be made for the whole tumor area, regardless of hot spots.
All mononuclear cells including lymphocytes and plasma cells should be scored (granulocytes and other polymorphonuclear leukocytes are excluded).
The quantitative assessment of other mononuclear cells such as dendritic cells and macrophages is currently not recommended.
TILs should be reported for the intratumoral lymphocytes (as first proposed by Denkert in 2010).
Stromal lymphocytes (Str-Ly) are defined as the percentage of tumor stroma area that contains a lymphocytic infiltrate without direct contact to tumor cells.
|
20 weeks
|
Number of participants with treatment-related adverse events as assessed by CTCAE v.4.03
Time Frame: 20 weeks
|
20 weeks
|
|
Evaluation of the drug delivery
Time Frame: 20 weeks
|
Patient compliance for paclitaxel and carboplatin and for epirubicin and cyclophosphamide will be assessed by the investigator and/or study personnel at each patient visit. To accurately determine the patient's drug exposure throughout the study, the following information must be reported on the Drug Administration Record CRF pages and in the source document. Planned dose administration, Actual total daily dose administrated, Regimen, Start and end date of drug administration, Dose change, Reason for dose change |
20 weeks
|
Evaluation of clinical response rate (RECIST 1.1) by mammography and sonography in breast and axilla.
Time Frame: 20 weeks
|
20 weeks
|
|
Evaluation of breast-conserving surgery rate
Time Frame: 20 weeks
|
20 weeks
|
|
Evaluation of progression free survival
Time Frame: 20 weeks
|
20 weeks
|
|
Evaluation of overall survival
Time Frame: 20 weeks
|
20 weeks
|
|
Evaluation of percentage of patients with BRCA1 or BRCA2 in this population.
Time Frame: 20 weeks
|
20 weeks
|
|
genome analysis on tissue samples
Time Frame: 20 weeks
|
Tumor tissue samples (FFPE) for genetic research will be obtained from consenting patients both at screening and at surgery. Genome analysis will be performed on (1) DNA extracted from EDTA blood (10ml) collected at the start of the treatment and (2) on DNA extracted from FFPE tumor tissue collected before the start of the neoadjuvant chemotherapy and after surgery. |
20 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christel Fontaine, Dr., Universitair Ziekenhuis Brussel
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Cyclophosphamide
- Carboplatin
- Paclitaxel
- Epirubicin
Other Study ID Numbers
- BSMO-2014-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
Clinical Trials on Epirubicin
-
Mansoura UniversityCompleted
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisActive, not recruiting
-
PfizerCompletedAdenocarcinomaUnited States
-
Fudan UniversityCompleted
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Eli Lilly and CompanyCompletedBreast CancerArgentina, Belgium, Brazil, Mexico, Portugal
-
Tao OUYANGCompleted
-
University of Medicine and Dentistry of New JerseyNational Cancer Institute (NCI)TerminatedBreast CancerUnited States
-
Ankara Training and Research HospitalRecruitingBladder Cancer | Superficial Bladder Cancer | Tumor Recurrence | Epirubicin Adverse ReactionTurkey
-
PfizerCompleted